Characteristics of the three groups
| Total | Group 1 | Group 2 | Group 3 | p-value | |
|---|---|---|---|---|---|
| (RF+ and/or ACPA+) | (RF−/ACPA−) | (Missing ACPA/RF−) | |||
| Number of patients (%) | |||||
| Baseline | 2191 | 1276 (58.2) | 497 (22.7) | 225 (10.3) | N/A |
| 3 months | 1743 | 1062 (60.9) | 359 (20.6) | 171 (9.8) | |
| DAS28, mean ± SEM | |||||
| Baseline | 4.89±0.04 | 4.92±0.05 | 4.81±0.07 | 4.90±0.10 | 0.45 0.33 |
| 3 months | 3.55±0.04 | 3.51±0.05 | 3.60±0.09 | 3.70±0.13 | 0.33 |
| Meets 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis, no. (%) ACR2010b | 1569 (78.8) | 1138 (89.7) | 293 (59.0) | 138 (61.6) | <0.001* |
| On Methotrexate, no. (%) | |||||
| Baseline | 1296 (64.9) | 889 (69.7) | 283 (56.9) | 124 (55.1) | <0.001* |
| 3 months | 1194 (75.0) | 830 (78.2) | 250 (69.6) | 114 (66.7) | <0.001* |
| Number of DMARDs, mean ± SEM | |||||
| Baseline | 1.31±0.02 | 1.41±0.02 | 1.17±0.04 | 1.05±0.05 6 | <0.001* |
| 3 months | 1.60±0.02 | 1.67±0.03 | 1.51±0.05 | 1.36±0.06 | <0.001* |
Significant values (p<0.05) are marked with an asterisk (*).